Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting, 18909-18910 [2017-08189]
Download as PDF
18909
Federal Register / Vol. 82, No. 77 / Monday, April 24, 2017 / Notices
ANNUAL BURDEN ESTIMATES
Total/annual
number of
respondents
Instrument
Communications for site visit planning ............................................................
Discussion guide: Individual and small-group interviews ................................
Estimated Total Annual Burden
Hours: 96.
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Planning, Research and Evaluation, 330
C Street SW., Washington, DC 20201,
Attn: OPRE Reports Clearance Officer.
All requests should be identified by the
title of the information collection. Email
address: OPREinfocollection@
acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
be sent directly to the following: Office
of Management and Budget, Paperwork
Reduction Project, Email: OIRA_
SUBMISSION@OMB.EOP.GOV, Attn:
Desk Officer for the Administration for
Children and Families.
Mary Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2017–08167 Filed 4–21–17; 8:45 am]
BILLING CODE 4184–29–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0001]
Gastroenterology and Urology Devices
Panel of the Medical Devices Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Gastroenterology and
Urology Devices Panel of the Medical
Devices Advisory Committee. The
general function of the committee is to
provide advice and recommendations to
the Agency on FDA’s regulatory issues.
The meeting will be open to the public.
jstallworth on DSK7TPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
13:48 Apr 21, 2017
Jkt 241001
6
60
The meeting will be held on May
17, 2017, from 8 a.m. to 6 p.m.
ADDRESSES: Hilton Washington, DC/
North, Salons A, B, C, and D, 620 Perry
Pkwy., Gaithersburg, MD 20877. The
hotel’s telephone number is 301–977–
8900. Answers to commonly asked
questions including information
regarding special accommodations due
to a disability, visitor parking, and
transportation may be accessed at:
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm408555.htm.
DATES:
FOR FURTHER INFORMATION CONTACT:
Patricio G. Garcia, Center for Devices
and Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. G610, Silver Spring,
MD 20993–0002, Patricio.Garcia@
fda.hhs.gov, 301–796–6875, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://www.fda.
gov/AdvisoryCommittees/default.htm
and scroll down to the appropriate
advisory committee meeting link, or call
the advisory committee information line
to learn about possible modifications
before coming to the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: On May 17, 2017, the
committee will discuss, make
recommendations, and vote on
information regarding the premarket
approval application (PMA) for the
TRANSMEDICS ORGAN CARE
SYSTEM (OCS)—Lung System, by
TransMedics, Inc. The proposed
Indication for Use, as stated in the PMA,
is as follows: The TRANSMEDICS
ORGAN CARE SYSTEM (OCS) Lung
System is a portable organ perfusion,
ventilation, and monitoring medical
device intended to preserve donor lungs
in a near physiologic, ventilated, and
perfused state for transplantation.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
PO 00000
Frm 00021
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
1
1
Average
burden hours
per response
1
1.5
Total/annual
burden hours
6
90
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before May 8, 2017. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before April 28,
2017. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by May 1, 2017.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Artair Mallett
at artair.mallett@fda.hhs.gov or 301–
796–9638 at least 7 days in advance of
the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
E:\FR\FM\24APN1.SGM
24APN1
18910
Federal Register / Vol. 82, No. 77 / Monday, April 24, 2017 / Notices
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: April 18, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation and Analysis.
[FR Doc. 2017–08189 Filed 4–21–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0001]
Safe Use Symposium: A Focus on
Reducing Preventable Harm From
Drugs in the Outpatient Setting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public symposium.
The Food and Drug
Administration’s (FDA or Agency)
Center for Drug Evaluation and
Research, Professional Affairs and
Stakeholder Engagement Staff (PASES),
is hosting a 1-day public symposium
entitled ‘‘Safe Use Symposium: A Focus
on Reducing Preventable Harm From
Drugs in the Outpatient Setting.’’ The
purpose of this symposium is to discuss
sources of preventable harm from drugs
in the outpatient setting and to
stimulate the exchange of ideas among
thought leaders on interventions to
reduce preventable harms and how
these interventions can be studied.
DATES: The public symposium will be
held on June 15, 2017, from 8 a.m. to 4
p.m.
ADDRESSES: The public symposium will
be held at FDA’s White Oak campus,
10903 New Hampshire Ave, Bldg. 31
(The Great Room C), Silver Spring, MD
20903. Entrance for the public
symposium participants (non-FDA
employees) is through Bldg. 1 where
routine security check procedures will
be performed. For parking and security
information, please refer to https://
www.fda.gov/AboutFDA/
WorkingatFDA/BuildingsandFacilities/
WhiteOakCampusInformation/
ucm241740.htm.
FOR FURTHER INFORMATION CONTACT:
Christine Lee, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Silver Spring, MD
20993–0002, 240–402–4228, email:
CDERSafeUseInitiative@fda.hhs.gov.
jstallworth on DSK7TPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
13:48 Apr 21, 2017
Jkt 241001
The Food
and Drug Administration’s (FDA) Center
for Drug Evaluation and Research,
Professional Affairs and Stakeholder
Engagement Staff (PASES), is hosting a
1-day public symposium entitled ‘‘Safe
Use Symposium: A Focus on Reducing
Preventable Harm From Drugs in the
Outpatient Setting.’’ The purpose of this
symposium is to discuss sources of
preventable harm from drugs in the
outpatient setting, such as the use of
inappropriate medications in particular
age groups, drug-drug interactions,
unintended exposures, and misuse; and
to stimulate the exchange of ideas
among thought leaders on interventions
to reduce preventable harms and how
these interventions can be studied. This
information may assist FDA in
identifying significant and unexplored
areas of preventable harm from drugs for
the purpose of funding future research
through the Safe Use Initiative. The
symposium will feature presentations
on sources of outpatient preventable
harms, possible interventions, and
future research topics. Areas to be
discussed include identifying drugs and
populations associated with a higher
risk of preventable harm, as well as
events which may be amenable to
interventions. Methods to measure the
effect of interventions and how to apply
these to the outpatient setting will also
be an important focus of discussion.
Presenters will represent
multidisciplinary backgrounds from
government, academia, patient safety
groups, health care industry, and
clinicians. There will be opportunities
for interaction between speakers and
attendees as well as question and
answer sessions.
Registration: There is no registration
fee to attend the public symposium.
Early registration is recommended
because seating is limited, and
registration will be on a first-come, firstserved basis. There will be no onsite
registration. Persons interested in
attending this symposium must register
online at https://wcms.fda.gov/FDAgov/
Drugs/NewsEvents/
ucm538670.htm?SSContributor=true.
For those without Internet access, please
contact Christine Lee (see FOR FURTHER
INFORMATION CONTACT) to register. If you
need special accommodations due to a
disability, please contact Christine Lee
at least 7 days in advance.
Transcripts: A transcript of the
symposium will be available for review
at the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852, and on the
Internet at https://www.regulations.gov
approximately 30 days after the
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
symposium. Transcripts will also be
available in either hard copy or on CD–
ROM, after submission of a Freedom of
Information request. The Freedom of
Information office address is available
on the Agency’s Web site at https://
www.fda.gov.
Dated: April 17, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–08182 Filed 4–21–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0001]
Vaccines and Related Biological
Products Advisory Committee; Notice
of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Vaccines and Related
Biological Products Advisory
Committee (VRBPAC). The general
function of the committee is to provide
advice and recommendations to the
Agency on FDA’s regulatory issues. The
meeting will be open to the public.
DATES: The meeting will be held on May
17, 2017, from 8:30 a.m. to 4:45 p.m.
ADDRESSES: FDA White Oak Campus,
10903 New Hampshire Ave., Building
31 Conference Center, the Great Room
(rm. 1503), Silver Spring, MD 20993–
0002. For those unable to attend in
person, the meeting will also be Web
Cast and will be available at the
following link: https://
collaboration.fda.gov/rsvvaccine0517.
Answers to commonly asked questions
including information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
FOR FURTHER INFORMATION CONTACT:
CAPT Serina Hunter-Thomas or
Rosanna Harvey, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 6307C,
Silver Spring, MD 20993–0002, at 240–
402–5771 serina.hunter-thomas@
fda.hhs.gov and 240–402–8072,
rosanna.harvey@fda.hhs.gov, or FDA
SUMMARY:
E:\FR\FM\24APN1.SGM
24APN1
Agencies
[Federal Register Volume 82, Number 77 (Monday, April 24, 2017)]
[Notices]
[Pages 18909-18910]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08189]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-0001]
Gastroenterology and Urology Devices Panel of the Medical Devices
Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the Gastroenterology and Urology
Devices Panel of the Medical Devices Advisory Committee. The general
function of the committee is to provide advice and recommendations to
the Agency on FDA's regulatory issues. The meeting will be open to the
public.
DATES: The meeting will be held on May 17, 2017, from 8 a.m. to 6 p.m.
ADDRESSES: Hilton Washington, DC/North, Salons A, B, C, and D, 620
Perry Pkwy., Gaithersburg, MD 20877. The hotel's telephone number is
301-977-8900. Answers to commonly asked questions including information
regarding special accommodations due to a disability, visitor parking,
and transportation may be accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
FOR FURTHER INFORMATION CONTACT: Patricio G. Garcia, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. G610, Silver Spring, MD 20993-0002,
Patricio.Garcia@fda.hhs.gov, 301-796-6875, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area). A notice in the Federal Register about last minute modifications
that impact a previously announced advisory committee meeting cannot
always be published quickly enough to provide timely notice. Therefore,
you should always check the Agency's Web site at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate
advisory committee meeting link, or call the advisory committee
information line to learn about possible modifications before coming to
the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: On May 17, 2017, the committee will discuss, make
recommendations, and vote on information regarding the premarket
approval application (PMA) for the TRANSMEDICS ORGAN CARE SYSTEM
(OCS)--Lung System, by TransMedics, Inc. The proposed Indication for
Use, as stated in the PMA, is as follows: The TRANSMEDICS ORGAN CARE
SYSTEM (OCS) Lung System is a portable organ perfusion, ventilation,
and monitoring medical device intended to preserve donor lungs in a
near physiologic, ventilated, and perfused state for transplantation.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting
link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before May
8, 2017. Oral presentations from the public will be scheduled between
approximately 1 p.m. and 2 p.m. Those individuals interested in making
formal oral presentations should notify the contact person and submit a
brief statement of the general nature of the evidence or arguments they
wish to present, the names and addresses of proposed participants, and
an indication of the approximate time requested to make their
presentation on or before April 28, 2017. Time allotted for each
presentation may be limited. If the number of registrants requesting to
speak is greater than can be reasonably accommodated during the
scheduled open public hearing session, FDA may conduct a lottery to
determine the speakers for the scheduled open public hearing session.
The contact person will notify interested persons regarding their
request to speak by May 1, 2017.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Artair Mallett at artair.mallett@fda.hhs.gov or 301-796-9638 at
least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/
AdvisoryCommittees/AboutAdvisoryCommittees/
[[Page 18910]]
ucm111462.htm for procedures on public conduct during advisory
committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: April 18, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation and Analysis.
[FR Doc. 2017-08189 Filed 4-21-17; 8:45 am]
BILLING CODE 4164-01-P